July 23, 2014 4:20 AM ET

Pharmaceuticals

Company Overview of Lithera, Inc.

Company Overview

Lithera, Inc. develops pharmaceutical and biomedical products that address medical and lifestyle indications in ophthalmology and aesthetic medicine. It offers LIPO-102, an injectable pharmaceutical product for local and selective fat reduction therapy. The company’s LIPO-102 is also used for the treatment of symptomatic exophthalmos associated with thyroid-related eye disease and the reduction of abdominal adiposity. Lithera, Inc. was founded in 2007 and is based in San Diego, California.

9191 Towne Centre Drive

Suite 400

San Diego, CA 92122

United States

Founded in 2007

Phone:

858-750-1008

Fax:

858-750-1013

Key Executives for Lithera, Inc.

Chief Executive Officer
Age: 54
Founder and Director
Age: 48
Vice President of Finance and Administration
Chief Medical Officer
Age: 67
Vice President of Pharmaceutical Development & Manufacturing
Compensation as of Fiscal Year 2014.

Lithera, Inc. Key Developments

Lithera, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 08:40 AM

Lithera, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 08:40 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: George W. Mahaffey, Chief Executive Officer, President and Director.

Lithera, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 10:00 AM

Lithera, Inc. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-04-2014 10:00 AM. Venue: Marriott Copley Place Hotel, Boston, Massachusetts, United States. Speakers: George W. Mahaffey, Chief Executive Officer, President and Director.

Lithera, Inc. Appoints Lincoln Krochmal as Chief Medical Officer

Lithera, Inc. announced the appointment of Lincoln Krochmal, M.D., as Chief Medical Officer. This appointment reflects the continued growth of Lithera as it prepares to enter late-stage clinical trials and to commercialize its lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection). Krochmal is a board-certified dermatologist and an authority on the development and commercialization of products for the dermatology and aesthetics markets. During his more than 30 year career, he played a pivotal role in the approval of 15 NDAs/ANDAs for new prescription topical dermatologicals including LacHydrin(R), Ultravate(R), Dovonex(R), Evoclin(R), Verdeso(R), Olux-E(R), Extina(R) and multiple consumer OTC products while with Unilever. Prior to Lithera, Dr. Krochmal was President and Chief Executive Officer of Excaliard Pharmaceuticals, an aesthetics company acquired by Pfizer, Inc., which developed novel treatments for the reduction of skin scarring.

Similar Private Companies By Industry

Company Name Region
Applied Pharma Research USA, LLC United States
BPT Pharmaceuticals Inc. United States
P2D, Inc. United States
Aeglea BioTherapeutics Holdings, LLC United States
Park Compounding Pharmacy, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lithera, Inc., please visit www.lithera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.